San Diego-based biopharmaceuticals developer Imprimis Pharmaceuticals announced this morning that it has acquired intellectual property from Novel Drug Solutions and Eye Care Northwest. Imprimis said the IP includes a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Financial terms of the acquisition were not disclosed. Imprimis said the acquisition allows it to pursue commercial development in the cataract surgery market.
Top NewsWednesday, August 28, 2013
Imprimis Pharmaceuticals In Intellectual Property Deal